Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy

Ketamine

Brief Summary

To test the current standard of care (SOC) treatment for laparoscopic cholecystectomy with a group receiving SOC + additional perioperative analgesics in terms of postoperative abilities, PONV, pain and discharge time from the PACU

Intervention / Treatment

  • Drug: Gabapentin
  • Drug: S-ketamine
  • Drug: Lidocaine
  • Drug: Droperidol

Condition or Disease

  • Cholecystolithiasis

Phase

Study Design

Study type: Interventional
Status: Unknown status
Study results: No Results Available
Age: 18 Years and older   (Adult, Older Adult)
Enrollment: 60 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Oct 05, 2020
Primary Completion: Aug 31, 2020
Completion Date: Aug 31, 2020
Study First Posted: Sep 21, 2005
Results First Posted: Aug 31, 2020
Last Updated: Sep 21, 2005

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Location

Copenhagen, Denmark
Hvidovre, Denmark

Aim of the study: to compare postoperative complaints (PONV, pain, etc) and PACU discharge time between two groups:

  • A: standard of care (SOC)receiving intraoperative dexamethasone, ondansetron, ketorolac, and general anaesthesia with propofol, remifentanil and cisatracurium
  • B: SOC + preoperative gabapentin, intraoperative lidocain infusion, s-ketamin and droperidol.

Primary endpoints:

  • postoperative abilities over time
  • discharge time from PACU according to fixed criteria
  • consumption of analgesics and antiemetics in the PACU

Secondary endpoints:

  • degree of nursing requirements at the PACU
  • General tolerability of the regimes

Eligibility Criteria

Sex: All
Minimum Age: 18

More Details

NCT Number: NCT00209885
Other IDs: OMA-LC01
Study URL: https://ClinicalTrials.gov/show/NCT00209885
Last updated: Jan 27, 2021